Skip to main content
Top
Published in: Annals of Surgical Oncology 12/2021

01-11-2021 | NSCLC | Thoracic Oncology

Intraoperative Lymph Node Management During Non-small Cell Lung Cancer Surgery

Authors: Michael R. Gooseman, MD, Alessandro Brunelli, MD

Published in: Annals of Surgical Oncology | Issue 12/2021

Login to get access

Excerpt

The current issue of the Annals of Surgical Oncology publishes an excellent study by Handa et al.1 This work supports the use of systematic lymph node dissection in patients with hypermetabolic non-small cell lung cancer (NSCLC) and adds further clarification on what is a highly contentious and debated matter. Lymph node management during lung cancer surgery continues to be the subject of significant debate and analysis in the thoracic surgical community. Lymphadenectomy and lymph node sampling are fundamental in allowing for accurate staging with potential for survival benefit. The various intraoperative techniques relating to lymph node assessment demonstrate a lack of definitive indications regarding the best option. Given this, over the last couple of decades, there have been numerous studies assessing surgical lymph node management with factors such as surgical morbidity, recurrence rate, and long-term survival. …
Literature
2.
go back to reference Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-313S.CrossRef Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e278S-313S.CrossRef
3.
go back to reference Landreneau RJ, Normolle DP, Christie NA, et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J Clin Oncol. 2014;32(23):2449–55.CrossRef Landreneau RJ, Normolle DP, Christie NA, et al. Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. J Clin Oncol. 2014;32(23):2449–55.CrossRef
4.
go back to reference Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg. 2014;147(2):754–62. (discussion 762–754) Altorki NK, Yip R, Hanaoka T, et al. Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. J Thorac Cardiovasc Surg. 2014;147(2):754–62. (discussion 762–754)
5.
go back to reference Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106(1):178–83.CrossRef Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg. 2018;106(1):178–83.CrossRef
7.
go back to reference Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23 Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–23
8.
go back to reference Aokage K, Yoshida J, Ishii G, et al. Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid? Lung Cancer. 2010;70(2):163–7.CrossRef Aokage K, Yoshida J, Ishii G, et al. Subcarinal lymph node in upper lobe non-small cell lung cancer patients: is selective lymph node dissection valid? Lung Cancer. 2010;70(2):163–7.CrossRef
9.
go back to reference Lardinois D, De Leyn P, Van Schil P, Rami Porta R, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. EJCTS. 2006;30(5):787–92. Lardinois D, De Leyn P, Van Schil P, Rami Porta R, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. EJCTS. 2006;30(5):787–92.
10.
go back to reference Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg. 1999;16(Suppl 1):S17-24.CrossRef Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer: how should it be done? Eur J Cardiothorac Surg. 1999;16(Suppl 1):S17-24.CrossRef
11.
go back to reference Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M; Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg. 2001;122(4):803–8 Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M; Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg. 2001;122(4):803–8
Metadata
Title
Intraoperative Lymph Node Management During Non-small Cell Lung Cancer Surgery
Authors
Michael R. Gooseman, MD
Alessandro Brunelli, MD
Publication date
01-11-2021
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2021
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-10039-5

Other articles of this Issue 12/2021

Annals of Surgical Oncology 12/2021 Go to the issue